about
Deciphering the divergent roles of progestogens in breast cancer.Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificityPharmacological targeting of the transcription factor SOX18 delays breast cancer in mice.Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.ERRα induces H3K9 demethylation by LSD1 to promote cell invasion.FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3.Cell cycle-coupled expansion of AR activity promotes cancer progression.Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions.Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugatesCorrection: A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugatesIdentification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alphaAuthor Correction: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment responseELF5 modulates the estrogen receptor cistrome in breast cancerFine-mapping of 150 breast cancer risk regions identifies 191 likely target genesARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment responseGeneral dual functionalisation of biomacromolecules via a cysteine bridging strategy
P50
Q30240711-5A2A64A9-7650-4BA7-BCE0-73A8C8A2708EQ37582438-E8852F29-D52F-4A77-B798-CA03407EC434Q37616736-0FB2777D-6F76-45DE-8BEB-B58E1A5E43C9Q38753546-4546DBEC-1A9B-4A95-A2B1-3DA3C36753EFQ38872759-A0886314-1882-49DD-8966-7FFDB8821E0BQ39674360-3B5E0093-52C5-409A-9D81-88F3D79CA818Q40565537-F9AC1424-ADBA-4FF7-BBAE-A6C690395215Q44871921-548AC013-F7F3-47ED-9710-CFCC7063F15AQ45054466-318A2950-D3D3-4D82-B224-8FCC54249A3AQ51019461-3B613434-232E-4A3C-9575-A23F6C8CD74AQ52730266-64B9EA80-B002-40DE-92E4-08C4113531D5Q59945270-0D778F19-2EC8-4225-96C4-2F7AF691D788Q59945271-5C93A40E-2A23-4077-9E07-99B497BB2D47Q64061185-241B19E5-2061-44F8-A2C0-599BB2D75CDEQ89475490-B758C0F8-5180-4434-A990-24C4A38DF073Q92375650-63C9E356-BDAD-4899-B87D-8177DD81E8B5Q92480972-0A765287-6602-47E3-B164-C1B911B0BB61Q92491751-C791AA3A-A2C7-46EA-B620-E7A729F4E576Q95307192-806E82AF-6FAD-4DAF-BD26-5CD7ED1B9F7A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jason S Carroll
@nl
Jason S Carroll
@sl
Jason S. Carroll
@en
Jason S. Carroll
@es
type
label
Jason S Carroll
@nl
Jason S Carroll
@sl
Jason S. Carroll
@en
Jason S. Carroll
@es
prefLabel
Jason S Carroll
@nl
Jason S Carroll
@sl
Jason S. Carroll
@en
Jason S. Carroll
@es
P106
P1153
57193223536
P31
P496
0000-0003-3643-0080
P6023
2067821951